-+ 0.00%
-+ 0.00%
-+ 0.00%

Aprea Therapeutics Announces ACESOT-1051 Enrollment Is Accelerating; Clinical Data Presentation Planned For Q4 2026

Benzinga·07/30/2026 12:03:30
Listen to the news
  • Next clinical data update from the ongoing Phase 1 dose escalation ACESOT-1051 trial anticipated at a medical meeting in Q4 2026, providing a near-term opportunity to demonstrate continued clinical progress with APR-1051
  • Enrollment in ACESOT-1051 is accelerating as the Company advances dose escalation and amasses the clinical data needed to inform dose selection and subsequent development
  • Aprea plans to advance APR-1051 in uterine serous carcinoma (USC) and Cyclin E–overexpressing platinum-resistant ovarian cancer (PROC) while also evaluating combination regimens with standard of care in HPV-positive head and neck cancer and colorectal cancer, utilizing dose levels that have shown single-agent activity and cleared safety review
  • The expanded development strategy builds on emerging single-agent activity and positions APR-1051 across biomarker-defined indications where WEE1 inhibition may address significant unmet medical need